Zoetis Inc. (NYSE:ZTS) Position Lifted by Diamant Asset Management Inc.

Diamant Asset Management Inc. raised its stake in Zoetis Inc. (NYSE:ZTS) by 5.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,705 shares of the company’s stock after purchasing an additional 240 shares during the period. Diamant Asset Management Inc.’s holdings in Zoetis were worth $767,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Greenup Street Wealth Management LLC lifted its holdings in Zoetis by 2.1% during the 4th quarter. Greenup Street Wealth Management LLC now owns 8,243 shares of the company’s stock worth $1,343,000 after buying an additional 168 shares during the last quarter. Nilsine Partners LLC lifted its stake in Zoetis by 4.3% during the fourth quarter. Nilsine Partners LLC now owns 27,846 shares of the company’s stock worth $4,537,000 after purchasing an additional 1,151 shares during the last quarter. Berkshire Bank bought a new stake in Zoetis during the fourth quarter valued at $202,000. Baldwin Wealth Partners LLC MA raised its holdings in shares of Zoetis by 5.6% during the fourth quarter. Baldwin Wealth Partners LLC MA now owns 74,961 shares of the company’s stock worth $12,213,000 after purchasing an additional 4,002 shares during the period. Finally, Kavar Capital Partners Group LLC lifted its position in shares of Zoetis by 86.8% in the 4th quarter. Kavar Capital Partners Group LLC now owns 10,268 shares of the company’s stock worth $1,673,000 after buying an additional 4,772 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $173.07 on Tuesday. The firm has a market capitalization of $78.08 billion, a PE ratio of 32.53, a P/E/G ratio of 2.57 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The company’s 50 day simple moving average is $170.10 and its 200 day simple moving average is $179.75.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the business posted $1.36 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, equities research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.16%. Zoetis’s dividend payout ratio is currently 37.59%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ZTS shares. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.